Komori
Medikit (7749) · InitiativeAdvanced

Repurchase of 150,000 Treasury Shares

First written in FY2021-Q3. 4 of 7 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.

7entries
6years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2021 – FY2022AdvancedFY2024-Q3 – FY20262021: 220212022: 220222023: 120232024: 120242025: 020252026: 12026
Same theme, other companies
Flexible Shareholder Returns and Capital Policy Through Board AuthorityA theme 528 companies write about · 0 as a headwind · 529 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 199 companies compared. The sentences above are computed from all 199.Comparing 200 of the theme's 529 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Status of the resolution at the Board of Directors meeting on 12 November 2025 (acquisition period: 13 November 2025 to 13 November 2025): 150,000 shares, ¥409,800,000. … Treasury shares acquired during the fiscal year: 150,000 shares, ¥409,800,000.」

    Based on the Board of Directors resolution of November 2025, the company acquired 150,000 shares for ¥409,800,000.
  2. FY2024-Q3AdvancedAnnual report

    「The company confirmed that acquiring the shares as treasury shares would contribute to improving earnings per share (EPS), return on equity (ROE) and other measures of capital efficiency, as well as to returning profits to shareholders, and would not conflict with its basic policy of securing retained earnings in preparation for flexible and strategic development and investment. Class of shares acquired: Common shares Total number of shares acquired: 2,000,000 shares Total acquisition price: ¥4,776,000,000 Acquisition date: 31 January 2024」

    In response to the largest shareholder’s intention to sell, the company conducted a tender offer for treasury shares. It acquired 2,000,000 shares for ¥4,776 million to improve capital efficiency, including EPS and ROE, return profits to shareholders, and secure funds for development and investment.
  3. FY2023SoftenedAnnual report

    「Status of the resolution at the Board of Directors meeting on 16 December 2021 (acquisition period: 17 December 2021 to 30 June 2022): 144,000 shares, ¥400,000,000. … Treasury shares acquired during the fiscal year: none. Total number and aggregate value of shares remaining under the resolution: 117,200 shares, ¥334,114,100.」

    No additional acquisitions were made during the fiscal year under the treasury share acquisition limit, under which 26,800 shares had been acquired by the previous fiscal year. The unutilized balance was 117,200 shares and ¥334,114,100.
  4. FY2022AdvancedAnnual report

    「Status of the resolution at the Board of Directors meeting on 16 December 2021 (acquisition period: 17 December 2021 to 30 June 2022): 144,000 shares, ¥400,000,000. … Treasury shares acquired during the fiscal year: 26,800 shares, ¥65,885,900.」

    Following the acquisition of 150,000 shares completed in the previous fiscal year, the company acquired 26,800 treasury shares for ¥65,885,900 during FY2022. Of the 144,000-share acquisition limit, 117,200 shares remained as of the fiscal year-end.
  5. FY2022-Q3AdvancedAnnual report

    「At a Board of Directors meeting held on 16 December 2021, the company resolved matters relating to the acquisition of treasury shares pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the same Act, and acquired 2,300 shares during the third-quarter accounting period through market purchases on the Tokyo Stock Exchange.」

    Following the acquisition of 150,000 treasury shares completed in the previous fiscal year, the company acquired 2,300 shares through market purchases during the current quarter.
  6. FY2021AchievedAnnual report

    「At a Board of Directors meeting held on 17 November 2020, the company resolved matters relating to the acquisition of treasury shares pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the same Act. Treasury shares acquired during the fiscal year totaled 150,000 shares for ¥447,150,000.」

    The company completed the acquisition of 150,000 treasury shares for an acquisition price of ¥447,150,000 based on a Board of Directors resolution during the fiscal year.
  7. FY2021-Q3First statedAnnual report

    「At a Board of Directors meeting held on 17 November 2020, the company resolved matters relating to the acquisition of treasury shares pursuant to Article 156 of the Companies Act as applied with the necessary changes under Article 165, paragraph 3 of the same Act, and acquired 150,000 shares during the third-quarter accounting period through an off-auction purchase of treasury shares on the Tokyo Stock Exchange using ToSTNeT-3.」

    The company has for the first time disclosed that, based on the Board of Directors resolution of 17 November 2020, it acquired 150,000 treasury shares through ToSTNeT-3 during the third-quarter accounting period.
Moved together

"Holding of 962,200 treasury shares" moved the same way as this thread, in the same document, in 4 of its 7 moves.

433322★123456
  1. ★This thread
  2. 1Holding of 962,200 treasury shares4×
  3. 2Launch and Improvement of Products with Safety Mechanisms and New Catheter Products3×
  4. 3Enhancement of Component Production Capacity at the Hyuga Plant and Hyuga No. 2 Plant3×
  5. 4Sales dependence on products related to hemodialysis3×
  6. 5Retained Earnings for Stable Dividends, Development and Investment2×
  7. 6Strengthening production capabilities through a division of roles between domestic and Vietnam sites2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Medikit's next results are scheduled for 2026-11-12. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.